Luis Z Avila

This inventor holds 38 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 12 EPO patents, primarily in Biotechnology Innovations. Top assignees: Genzyme Corporation, Focal, Inc., Aveta Biomics, Inc.. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Luis Z Avila. Retrieved from https://idiyas.com/inventor/luis-z-avila

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 (Patent Applications = 6)

% Patents Active = 81.6

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 14)

Average Co-Inventor Count = 4.7

ph-index = 16

Forward Citations = 1,590(Granted Patents)

Location History:

Suwanee, GA (US) (2011)
Suwanee, ES (2012)
Bridgewater, NJ (US) (2016 - 2021)
Arlington, MA (US) (1997 - 2023)

Company Filing History:

The University of Texas System

patents

5. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Oligosaccharide-Protein Conjugates

Glycoengineered Antibodies

Biodegradable Hydrogels

Polymerizable Polymers

Drug Delivery Systems

Chemically Modified Dendrimers

Radiopharmaceuticals

Polymer Conjugates

Hydroxy-Acid Cosmetics

Targeting Moieties

Bandwidth Optimization

Video Services

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12734207 - Methods and compositions for treating dysbiosis of oral microbiome (2026-09-15),

2. 12674003 - SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES (2026-07-07),

3. 12252504 - Oligosaccharide-protein conjugates (2025-03-18),

4. 11701402 - Polypharmaceutical drug compositions and related methods (2023-07-18),

5. 11697690 - Site-specific glycoengineering of targeting moieties (2023-07-11),

6. 11279725 - Oligosaccharide-protein conjugates (2022-03-22),

7. 11160874 - Glycoengineered antibody drug conjugates (2021-11-02),

8. 10995148 - Site-specific glycoengineering of targeting moieties (2021-05-04),

9. 10907142 - Oligosaccharides comprising an aminooxy group and conjugates thereof (2021-02-02),

10. 10464962 - Oligosaccharide-protein conjugates (2019-11-05),

11. 10064952 - Glycoengineered antibody drug conjugates (2018-09-04),

12. 9611357 - Chemically modified dendrimers (2017-04-04),

13. 9493498 - Oligosaccharide-protein conjugates (2016-11-15),

14. 9469850 - Oligosaccharides comprising an aminooxy group and conjugates thereof (2016-10-18),

15. 9283247 - Chemically modified dendrimers (2016-03-15),

Title: The Innovative Journey of Luis Z Avila: Pioneering Inventor in Arlington, MA

Introduction:

Luis Z Avila, a prolific inventor based in Arlington, MA, has made significant contributions to the field of pharmaceuticals through his groundbreaking patented innovations. With an impressive portfolio of 35 patents, Avila has been at the forefront of developing novel drug compositions and glycoengineering techniques to combat diseases like cancer.

Latest Patents:

1. Polypharmaceutical drug compositions and related methods: Avila's patent introduces compositions and methods for treating oral cancer by utilizing a poly-pharmaceutical drug with optimized ratios of bioactive compounds. This innovation aims to enhance the pharmacological characteristics for effective treatment.

2. Site-specific glycoengineering of targeting moieties: Avila's patent focuses on binding polypeptides and targeting moiety conjugates with site-specifically engineered glycan linkages. This advancement offers new possibilities in disease treatment by utilizing antigen-binding polypeptides with engineered glycans.

Career Highlights:

Avila has made significant contributions to renowned companies such as Genzyme Corporation and Focal, Inc., where he has played a pivotal role in driving innovation and advancing pharmaceutical research. His expertise and inventive spirit have been instrumental in developing cutting-edge solutions for complex medical challenges.

Collaborations:

Throughout his career, Avila has collaborated with esteemed professionals in the field, including coworkers like Arthur J Coury and Shikha P Barman. These collaborations have fostered a culture of innovation and knowledge sharing, leading to the successful development of revolutionary pharmaceutical technologies.

Conclusion:

Luis Z Avila's journey as an inventor showcases his unwavering commitment to pushing the boundaries of pharmaceutical research. Through his patented innovations and collaborative efforts, Avila continues to make a profound impact in revolutionizing the treatment landscape for diseases like cancer. His ingenuity and dedication serve as an inspiration for aspiring inventors and researchers in the quest for scientific excellence.

Profile summary based on public USPTO records.